INDEPENDENT ASSURANCE REPORT

To: The Stakeholders of AstraZeneca Plc

1. Introduction and Objectives of Work

Bureau Veritas UK Limited ("Bureau Veritas") has been engaged by AstraZeneca Plc ("AstraZeneca") to provide limited assurance over select sustainability metrics reported in its *Sustainability Data Annex 2024* (the 'Report'). The objective is to provide assurance to AstraZeneca and its stakeholders over the accuracy and reliability of the reported information and data.

2. Scope of Work

Subject to the exclusions listed below, the scope of our work was limited to assurance over the following information included within the Report for the period 1st January 2024 to 31st December 2024 (the 'Selected Information'):

- Access to healthcare:
    - People reached by Access to healthcare programmes (cumulative, million): Total people reached (all current and historic programmes)
    - Healthcare workers trained (cumulative): Total healthcare workers trained (all current and historic programmes)
    - Affordability: People reached by patient access programmes (cumulative, million); Product donation through patient assistance programmes (USD, million)
    - Philanthropy: Total community investment (USD, million); Non-profit organisations funded by AstraZeneca
- Environmental protection:
    - Scope 1, 2 and other GHG emissions (tonnes CO_2e): Scope 1 – Total; Scope 2 – Market based; Gross Scope 1 and 2 GHG emissions (Market-based); Scope 1 and 2 GHG emissions intensity (tonnes CO_2e per million of Total Revenue USD); Scope 2 – Location based; Outside of scopes (CO_2 of biological origin)
    - Road fleet: EV100: Battery electric vehicles (BEVs)
    - Energy consumption (MWh): Total energy consumption
    - Site energy management: EP100: Energy productivity (million of Total Revenue USD per GWh energy consumption); Renewable energy consumption – electricity and heat (MWh); Imported electricity – renewable; RE100: Renewable electricity consumption
    - Scope 3 GHG emissions (tonnes CO_2e): Category 1 – Purchased goods and services; Category 2 – Capital goods; Category 3 – Fuel and energy related (not Scope 1 or 2); Category 4 – Upstream transportation and distribution; Category 5 – Waste generated in operations; Category 6 – Business travel; Category 7 – Employee commuting; Category 8 – Upstream leased assets; Category 9 – Downstream transportation and distribution; Category 10 – Processing of sold products; Category 11 – Use of sold products; Category 12 – End-of-life treatment of sold products; Category 13 – Downstream leased assets; Category 14 – Franchises; Category 15 – Investments; Gross Scope 3 GHG emissions; Scope 3 GHG emissions intensity (tonnes CO_2e per million of Total Revenue USD); Share of primary activity data in Scope 3 reporting
    - Supply chain engagement (% spend with verified Science Based Targets (SBTs)): Category 1 – Purchased goods and services Category 2 – Capital goods; Category 4 – Upstream transportation and distribution; Category 6 – Business travel

- Safe Active Pharmaceutical Ingredients (API) discharges: Safe API discharges for AstraZeneca sites; Safe API discharges from suppliers
- Resource efficiency: Total syntheses that meet resource efficiency target at launch
- Product value chain environmental impact: Paper-based product packaging materials supplied from sustainable sources
- Water use within site water footprint, excluding non-contact cooling water: Total (million m^3); Chemical oxygen demand – effluent leaving our sites (tonnes)[1]
- Waste management: Total waste (tonnes)
- Non-hazardous waste (tonnes): Total non-hazardous waste; Non-hazardous waste recycled; Non-hazardous waste to landfill
- Hazardous waste (tonnes): Total hazardous waste; Hazardous waste recycled; Hazardous waste to landfill
- AZ Forest (cumulative): Number of trees planted
- Compliance summary: Financial penalties relating to Prosecutions, Enforcement actions, Regulatory warning/alerts, Other environmental compliance matters, Awaiting regulator outcome or AstraZeneca investigation ongoing, Significant environmental violations (USD)

- Ethics and transparency:
  - Business conduct: Active employees trained on Code of Ethics; Instances of non-compliance with the Code of Ethics; Concerns reported through the company helpline; Percentage of employees who feel we have a speak up culture
  - Clinical trial transparency (all cumulative): Studies shared with external research teams; Publicly available trial summaries
  - Human rights: Countries[2] that completed the Human rights survey; Countries that have a relationship with trade unions
  - Cybersecurity and data privacy: Number of material cybersecurity incidents; Number of material breaches involving personal data
  - Responsible supply chain: High-risk supplier audits; Percentage of suppliers by spend assessed by EcoVadis; Percentage of suppliers by spend assessed by EcoVadis that achieve >45
  - Animal use standards: Total number of animals
  - Human biological samples: Active projects using human foetal tissue (hFT)
  - Inclusion and diversity: Women representation of AstraZeneca employees; Women in management – Senior Middle management; Women representation on Senior Executive Team (SET); Women representation on Board of Directors; Ethnic minority representation for US employees; Percentage of employees age <30; Percentage of employees age 30-49; Percentage of employees age ≥50
  - Workforce safety and health: Total reportable injury rate (per million hours worked) (employees); Collisions (per million kilometres driven); Occupational illness rate (per million hours worked) (employees); Lost time injury rate (per million hours worked) (employees); Lost time injury rate (per million hours worked) (construction contractors); Fatalities (employees); Fatalities (contractors)

[1] AstraZeneca utilises the volume of effluent leaving sites to calculate the Chemical Oxygen Demand in tonnes.
[2] 'Countries' refers to AstraZeneca operations, in countries where they have employees.

- Employee satisfaction: Employee belief that in the last 12 months, I have improved my existing skills, or learned new skills, or had a development opportunity; Employee belief that AstraZeneca is a great place to work
- Talent attraction and retention: Total amount spent on upskilling employees (USD, million); Total learning hours; Average learning hours; Employee overall promotion rate; Voluntary employee turnover – recent hires; Voluntary employee turnover – total; Employee turnover
- Patient safety and product quality: Number of inspections from health authorities related to Good Manufacturing Practice; Number of critical findings from health authorities relating to Good Manufacturing Practice; Number of product recalls
- US Food and Drug Administration (FDA) Statistics: Total FDA recalls; Total FDA observations; Total FDA inspections
- Sustainable innovation: Number of New Molecular Entities (NMEs) approvals (cumulative); Number of pipeline progression events; Number of regulatory events

3. Reporting Criteria

The Selected Information needs to be read and understood together with the AstraZeneca defined criteria and methodologies, as set out at the following locations:

- Sustainability Data Reporting Criteria 2024: https://www.astrazeneca.com/content/dam/az/Sustainability/2025/pdf/Sustainability-Data-Reporting-Criteria-2024.pdf
- Greenhouse Gas Reporting Methodology 2024:

  https://www.astrazeneca.com/content/dam/az/Sustainability/2025/pdf/Greenhouse-Gas-Methodologies-2024.pdf

4. Limitations and Exclusions

Excluded from the scope of our work is assurance of information relating to:

- Data for the Healthy Lung programme for 2021, which feeds into the cumulative 2024 numbers of “People reached by access to healthcare programmes (cumulative, million): Total people reached (all current and historic programmes)” and the reported “Healthcare workers trained (cumulative): Total healthcare workers trained (all current and historic programmes)”;
- Activities outside the defined assurance period;
- Positional statements of a descriptive or interpretative nature, or of opinion, belief, aspiration or commitment to undertake future actions;
- Financial data taken from the Report and in some cases feeding into the calculation of Selected Information as these are audited by an external financial auditor. This includes but is not limited to any statements relating to production, sales, revenue and financial investments;
- Other information included in the Report other than the Selected Information.

The following limitations should be noted:

- For the metric ‘Number of trees planted’, AstraZeneca consolidates and reconciles data provided by its partners/third parties. The reliability of the reported data is dependent on the accuracy of data collection and monitoring arrangements of the partners.
- This limited assurance engagement relies on a risk based selected sample of sustainability data and the associated limitations that this entails.

- The reliability of the reported data is dependent on the accuracy of metering and other production measurement arrangements employed at site level, not addressed as part of this assurance.
- This independent statement should not be relied upon to detect all errors, omissions or misstatements that may exist.

5. Responsibilities

This preparation and presentation of the Selected Information in the Report are the sole responsibility of the management of AstraZeneca.

Bureau Veritas was not involved in the drafting of the Report or of the Reporting Criteria. Our responsibilities were to:

- obtain limited assurance about whether the Selected Information has been prepared in accordance with the Reporting Criteria;
- form an independent conclusion based on the assurance procedures performed and evidence obtained; and
- report our conclusions to the Directors of AstraZeneca.

6. Assessment Standard

We performed our work to a limited level of assurance in accordance with International Standard on Assurance Engagements (ISAE) 3000 Revised, Assurance Engagements Other than Audits or Reviews of Historical Financial Information (effective for assurance reports dated on or after December 15, 2015), issued by the International Auditing and Assurance Standards Board.

7. Summary of Work Performed

As part of our independent assurance, our work included:

1. Conducting interviews with relevant personnel of AstraZeneca;
2. Reviewing the data collection and consolidation processes used to compile Selected Information, including assessing assumptions made, and the data scope and reporting boundaries;
3. Reviewing documentary evidence provided by AstraZeneca;
4. Agreeing a selection of the Selected Information to the corresponding source documentation;
5. Reviewing AstraZeneca's systems for quantitative data aggregation and analysis;
6. Assessing the disclosure and presentation of the Selected Information to ensure consistency with assured information.
7. Carrying out three virtual site visits, selected on a risk-based basis to: Canóvanas Puerto Rico, New South Wales Australia, Frederick USA;
8. Carrying out two physical site visits, selected on a risk-based basis to: Athlone Ireland, Snäckviken Sweden;
9. Reperforming a selection of aggregation calculations of the Selected Information;

A 5% materiality threshold was applied to this assurance. It should be noted that the procedures performed in a limited assurance engagement vary in nature and timing from, and are less in extent than for, a reasonable assurance engagement. Consequently, the level of assurance obtained in a limited assurance engagement is substantially lower than the assurance that would have been obtained had a reasonable assurance engagement been performed.

8. Conclusion

On the basis of our methodology and the activities and limitations described above nothing has come to our attention to indicate that the Selected Information is not fairly stated in all material respects.

9. Statement of Independence, Integrity and Competence

Bureau Veritas is an independent professional services company that specialises in quality, environmental, health, safety and social accountability with over 190 years history. Its assurance team has extensive experience in conducting verification over environmental, social, ethical and health and safety information, systems and processes.

Bureau Veritas operates a certified[3] Quality Management System which complies with the requirements of ISO 9001:2015, and accordingly maintains a comprehensive system of quality control including documented policies and procedures regarding compliance with ethical requirements, professional standards, quality reviews and applicable legal and regulatory requirements which we consider to be equivalent to ISQM 1 & 2[4].

Bureau Veritas has implemented and applies a Code of Ethics, which meets the requirements of the International Federation of Inspections Agencies (IFIA)[5], across the business to ensure that its employees maintain integrity, objectivity, professional competence and due care, confidentiality, professional behaviour and high ethical standards in their day-to-day business activities. We consider this to be equivalent to the requirements of the IESBA code[6]. The assurance team for this work does not have any involvement in any other Bureau Veritas projects with AstraZeneca.

Bureau Veritas UK Ltd

Registered in England & Wales, Company Number: 1758622
Registered Office: Suite 206 Fort Dunlop, Fort Parkway, Birmingham, B24 9FD

London, 5th February 2025

[3] Certificate available on request
[4] International Standard on Quality Management 1 (Previously International Standard on Quality Control 1) & International Standard on Quality Management 2
[5] International Federation of Inspection Agencies – Compliance Code – Third Edition
[6] Code of Ethics for Professional Accountants issued by the International Ethics Standards Board for Accountants